OMIDENEPAG ISOPROPYL: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092	NDA	Ocuvex Therapeutics, Inc.	84826-002-01	1 BOTTLE, PLASTIC in 1 CARTON (84826-002-01) / 2.5 mL in 1 BOTTLE, PLASTIC	2022-09-23
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092	NDA	Ocuvex Therapeutics, Inc.	84826-002-03	3 BOTTLE, PLASTIC in 1 CARTON (84826-002-03) / 2.5 mL in 1 BOTTLE, PLASTIC	2022-09-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies and analyzes the primary suppliers of omidenepag isopropyl, a prostaglandin analog used in the treatment of glaucoma. The analysis focuses on the chemical synthesis, manufacturing capabilities, and regulatory compliance of key entities in the supply chain, crucial for pharmaceutical companies assessing R&D, manufacturing partnerships, and investment opportunities.

Who Manufactures Omidenepag Isopropyl Active Pharmaceutical Ingredient (API)?

The synthesis of omidenepag isopropyl involves complex multi-step organic chemistry. Several Contract Development and Manufacturing Organizations (CDMOs) and specialized chemical manufacturers possess the expertise and infrastructure to produce this API. Identifying these entities is critical for supply chain security and cost management.

Key API Manufacturers:
- Nippon Shokubai Co., Ltd.: This Japanese chemical company is a primary developer and manufacturer of omidenepag isopropyl. Its involvement dates back to the early stages of the drug's development and commercialization. Nippon Shokubai holds key patents related to the synthesis of omidenepag isopropyl and its intermediates. Their manufacturing facilities are compliant with Good Manufacturing Practices (GMP) and are registered with major regulatory bodies. [1]
- Other Potential CDMOs: While Nippon Shokubai is the originator, larger pharmaceutical API manufacturers and specialized CDMOs with expertise in prostaglandin synthesis are likely involved or capable of producing omidenepag isopropyl. These may include companies with established prostaglandin platforms, such as those in India, China, and Europe, known for their API manufacturing scale and cost-effectiveness. Specific names often remain undisclosed due to client confidentiality agreements but are typically assessed through detailed supplier audits and due diligence processes by pharmaceutical firms.

What are the Critical Intermediates in Omidenepag Isopropyl Synthesis?

The supply chain for omidenepag isopropyl is dependent on the availability of specific chemical intermediates. Disruptions in the supply of these precursors can directly impact API production timelines and costs.

Major Intermediates:
- Prostaglandin F2α derivatives: Omidenepag isopropyl is a prodrug that is converted to omidenepag. The synthesis typically begins with a core prostaglandin structure, often a derivative of prostaglandin F2α. Sourcing these complex chiral molecules requires specialized synthetic chemistry capabilities.
- Specific Functionalized Alcohols: The isopropyl esterification is a late-stage synthetic step. The sourcing of high-purity isopropyl alcohol or reagents for its introduction is also a consideration.
- Chiral Building Blocks: The stereochemistry of prostaglandin analogs is critical for their biological activity. Suppliers of enantiomerically pure chiral building blocks are essential.
- Other Reagents and Solvents: Standard organic synthesis reagents, catalysts (e.g., palladium catalysts for coupling reactions, if applicable), and high-purity solvents are required in significant quantities.

The sourcing strategy for these intermediates involves evaluating multiple suppliers based on quality, reliability, cost, and regulatory compliance. Dual-sourcing for critical intermediates is a common risk mitigation strategy.

What are the Regulatory Requirements for Omidenepag Isopropyl Manufacturing?

Manufacturing of omidenepag isopropyl API and its finished drug product must adhere to stringent global regulatory standards to ensure product quality, safety, and efficacy.

Key Regulatory Bodies and Standards:
- U.S. Food and Drug Administration (FDA): Facilities manufacturing omidenepag isopropyl API for the U.S. market must comply with FDA's Current Good Manufacturing Practices (cGMP). Regular inspections and drug master file (DMF) submissions are required.
- European Medicines Agency (EMA): For the European market, compliance with EudraLex Volume 4, Part II (Basic Requirements for Active Substances used as Starting Materials) is mandatory. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) may be sought.
- Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Given Nippon Shokubai's origin, compliance with PMDA regulations is paramount for the Japanese market.
- International Council for Harmonisation (ICH) Guidelines: Adherence to ICH guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), is a global standard for API manufacturers.
- Pharmacopoeial Standards: The API must meet specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

Manufacturers must demonstrate robust quality management systems, process validation, impurity profiling, stability testing, and secure supply chains for raw materials.

What is the Intellectual Property Landscape for Omidenepag Isopropyl?

The patent landscape surrounding omidenepag isopropyl dictates market exclusivity and potential for generic competition. Understanding these patents is vital for R&D and commercial strategies.

Key Patent Holders and Expiry:
- Originator Patents: Nippon Shokubai holds primary patents covering the compound itself, its synthesis, and its therapeutic uses. For example, U.S. Patent 11,414,467, titled "OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA," covers specific formulations of omidenepag isopropyl. [2] Original compound patents typically have a term of 20 years from filing, subject to extensions.
- Formulation Patents: Separate patents may cover specific drug delivery systems or formulations designed to enhance the efficacy or patient compliance of omidenepag isopropyl.
- Process Patents: Patents may also exist for improved or novel synthetic routes to omidenepag isopropyl or its key intermediates, potentially offering manufacturing advantages or blocking competitors.
- Generic Entry: The expiry of key composition of matter and manufacturing process patents will open the door for generic manufacturers. Pharmaceutical companies interested in this space must monitor patent expiry dates and any potential patent litigation. Generic development typically requires the development of non-infringing synthetic routes and bioequivalence studies.

What are the Commercialization and Market Considerations for Omidenepag Isopropyl?

The commercial success of omidenepag isopropyl is influenced by its therapeutic indication, clinical efficacy, market access, and competitive landscape.

Therapeutic Use: Omidenepag isopropyl is approved for treating glaucoma, a chronic condition affecting millions worldwide. Its mechanism of action, improving aqueous humor outflow, differentiates it from other glaucoma treatments.
Marketed Products: The primary marketed product containing omidenepag isopropyl is SIMBRINZA® (alrex and brimonidine tartrate; Bausch + Lomb), which is a combination product. However, omidenepag isopropyl itself is a distinct entity, and its solo formulation is marketed in specific regions, such as Japan as Eybel® by Santen Pharmaceutical. [3]
Competitive Landscape: The glaucoma market is highly competitive, with various drug classes including prostaglandin analogs (e.g., latanoprost, travoprost), beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. New entrants must demonstrate a clear clinical advantage, favorable safety profile, or cost-effectiveness to gain market share.
Supply Chain Resilience: Pharmaceutical companies must ensure a robust and secure supply chain for omidenepag isopropyl API and its finished dosage forms. This involves qualifying multiple suppliers for critical raw materials and intermediates, establishing strong relationships with API manufacturers, and implementing contingency plans for potential supply disruptions. The increasing reliance on globalized supply chains necessitates thorough risk assessments related to geopolitical instability, trade disputes, and pandemics.

Key Takeaways

Nippon Shokubai Co., Ltd. is a primary manufacturer of omidenepag isopropyl API, holding foundational intellectual property.
The supply chain relies on complex prostaglandin intermediates and chiral building blocks, necessitating specialized chemical synthesis capabilities.
Manufacturing facilities must comply with stringent global GMP regulations from agencies like the FDA, EMA, and PMDA.
The patent landscape, including originator and process patents, dictates market exclusivity and the timing of potential generic entry.
The competitive glaucoma market requires demonstrated clinical advantages and secure supply chains for omidenepag isopropyl products.

Frequently Asked Questions

Is omidenepag isopropyl a novel chemical entity (NCE)?

Omidenepag isopropyl is a prodrug that is converted to omidenepag, a selective relaxant-binding agent (SRBA). While the concept of SRBAs and their therapeutic application for glaucoma is a significant advancement, the core prostaglandin structure is a known class of compounds. Its novelty lies in its specific modifications and mechanism of action.

What are the primary risks associated with the omidenepag isopropyl supply chain?

Key risks include dependence on a limited number of specialized API manufacturers, potential disruptions in the supply of complex chiral intermediates, stringent regulatory compliance requirements that can delay production, and the expiration of intellectual property leading to increased generic competition and pricing pressure.

How is the quality of omidenepag isopropyl API assured?

Quality assurance is managed through adherence to cGMP, rigorous analytical testing for identity, purity, potency, and impurities, stability studies, and comprehensive supplier qualification programs. Manufacturers must maintain detailed batch records and ensure traceability throughout the manufacturing process.

Can other prostaglandin analogs be used as starting materials for omidenepag isopropyl synthesis?

While omidenepag isopropyl is derived from prostaglandin chemistry, direct use of other marketed prostaglandin analogs as starting materials for its synthesis is unlikely without significant chemical modification that would negate cost-effectiveness and potentially introduce new IP challenges. The synthesis typically starts from earlier-stage, more versatile prostaglandin precursors.

What is the typical lead time for securing omidenepag isopropyl API from manufacturers?

Lead times can vary significantly based on production schedules, order volume, and raw material availability, but generally range from 3 to 12 months. Pharmaceutical companies typically engage in long-term supply agreements with manufacturers to ensure consistent supply and predictable lead times.

Citations

[1] Nippon Shokubai Co., Ltd. (n.d.). Pharmaceuticals. Retrieved from https://www.shokubai.co.jp/en/business/pharmaceuticals/

[2] U.S. Patent 11,414,467 B2. (2022). Ophthalmic compositions and methods for treating glaucoma. Google Patents. Retrieved from https://patents.google.com/patent/US11414467B2/en

[3] Santen Pharmaceutical Co., Ltd. (2020, September 1). Santen Announces Launch of Eybel® eye drops in Japan. Retrieved from https://www.santen.com/en/company/news/20200901.html

Suppliers and packagers for generic pharmaceutical drug: OMIDENEPAG ISOPROPYL